Alps Advisors Inc. Acquires Shares of 19,825 HilleVax, Inc. (NASDAQ:HLVX)
Alps Advisors Inc. Acquires Shares of 19,825 HilleVax, Inc. (NASDAQ:HLVX)
Alps Advisors Inc. acquired a new stake in HilleVax, Inc. (NASDAQ:HLVX – Get Rating) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 19,825 shares of the company's stock, valued at approximately $217,000. Alps Advisors Inc. owned 0.06% of HilleVax at the end of the most recent quarter.
根據Alps Advisors Inc.提交給美國證券交易委員會(SEC)的最新Form 13F文件，Alps Advisors Inc.在第二季度收購了HilleVax，Inc.(HLVX-GET Rating)的新股份。該公司收購了該公司19,825股股票，價值約21.7萬美元。截至最近一個季度末，Alps Advisors Inc.持有HilleVax 0.06%的股份。
Other institutional investors also recently bought and sold shares of the company. Frazier Life Sciences Management L.P. acquired a new stake in HilleVax in the second quarter valued at approximately $101,493,000. Strs Ohio acquired a new stake in shares of HilleVax in the second quarter worth approximately $32,000. JPMorgan Chase & Co. acquired a new stake in shares of HilleVax in the second quarter worth approximately $76,000. Finally, TD Asset Management Inc. acquired a new stake in shares of HilleVax in the second quarter worth approximately $203,000.
其他機構投資者最近也買賣了該公司的股票。弗雷澤生命科學管理公司在第二季度收購了HilleVax的新股份，價值約101,493,000美元。俄亥俄州STRS在第二季度收購了HilleVax價值約3.2萬美元的新股份。摩根大通在第二季度增持了價值約76,000美元的HilleVax股票。最後，TD Asset Management Inc.在第二季度收購了價值約203,000美元的HilleVax新股。
HilleVax Stock Up 0.6 %
HilleVax股價上漲0.6%
Shares of NASDAQ:HLVX opened at $21.15 on Thursday. The company has a quick ratio of 34.77, a current ratio of 34.77 and a debt-to-equity ratio of 0.02. The business's 50 day moving average price is $19.37 and its 200-day moving average price is $14.70. HilleVax, Inc. has a 1 year low of $7.90 and a 1 year high of $24.42.
納斯達克：HLVX週四開盤報21.15美元。該公司的速動比率為34.77，流動比率為34.77，債務權益比為0.02。該業務的50日移動均線價格為19.37美元，200日移動均線價格為14.70美元。HilleVax，Inc.的一年低點為7.9美元，一年高位為24.42美元。
HilleVax Company Profile
HilleVax公司簡介
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
HilleVax，Inc.是一家臨牀階段的生物製藥公司，專注於開發和商業化新型疫苗。該公司正在開發HIL-214，這是一種基於病毒樣顆粒的候選疫苗，用於預防由諾沃克病毒感染引起的中到重度急性胃腸炎。該公司總部設在馬薩諸塞州波士頓。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on HilleVax (HLVX)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- 免費獲取StockNews.com關於HilleVax的研究報告(HLVX)
- 60/40的投資組合組合還在《時尚》雜誌上流行嗎？
- 機構對ADI的支持仍然很高
- 微軟股票：是時候備份卡車了嗎？
- Salesforce裁員，儘管面臨挑戰，但收入強勁
- 三隻CBD股票將主宰一個萌芽行業
Want to see what other hedge funds are holding HLVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HilleVax, Inc. (NASDAQ:HLVX – Get Rating).
想看看還有哪些對衝基金持有HLVX嗎？訪問HoldingsChannel.com獲取HilleVax，Inc.(納斯達克代碼：HLVX-GET Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.
接收HilleVax Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對HilleVax和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。